Bio-Path Holdings Inc. | Mutual Funds
Mutual Funds that own Bio-Path Holdings Inc.
Vanguard Extended Market Index Fund
78,343
0.69%
0
0%
07/31/2018
Vanguard Total Stock Market Index Fund
55,033
0.49%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
34,609
0.31%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
16,665
0.15%
0
0%
07/31/2018
Vanguard Balanced Index Fund
8,178
0.07%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
4,393
0.04%
0
0%
09/06/2018
Vanguard Total Stock Market Index Trust
3,126
0.03%
0
0%
07/31/2018
Meeder Spectrum Fund
2,731
0.02%
103
0%
06/29/2018
BlackRock Master Extended Market Index Series
1,672
0.02%
0
0%
01/31/2018
Vanguard Invt. Fds. ICVC - US Equity Index Fund
1,360
0.01%
0
0%
06/30/2018
| Address |
4710 Bellaire Boulevard
Bellaire Texas 77401
United States
|
|
Employees
|
- |
| Website |
http://www.biopathholdings.com |
| Updated |
07/08/2019 |
| Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its platform DNAbilize, uses P-ethoxy, which is a deoxyribonucleic acid backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. The company was founded by Peter Nielsen, Douglas P. |
